All In Biotech

NDA 020515 · Tersera

Zoladex

Goserelin · Implantation

Last checked: Nov 20, 2026Latest source record: May 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Dec 18, 1995

Approved uses

1

Original approval plus efficacy supplements

Registered trials

381

126 Phase 3, 47 recruiting

FAERS reports

13,568

12,237 serious, 2,422 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 18, 1995 Original approval · Type 6 - New Indication (no longer used)
1 products under this application
  • ZOLADEX · GOSERELIN 3.6MG · IMPLANT, IMPLANTATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Goserelin" as an intervention, any sponsor and status, largest first.

All 381 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death1,594
  • malignant neoplasm progression1,367
  • fatigue925
  • metastases to bone706
  • neutropenia680
  • nausea624
  • asthenia540
  • hot flush527
  • diarrhoea521
  • off label use493
  • pain492
  • arthralgia457

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004224
2005218
2006246
2007274
2008296
2009298
2010265
2011385
2012485
2013405
2014446
2015589
2016571
2017485
2018691
2019777
2020902
20211,190
20221,030
20231,255
20241,020
2025836
2026680

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zoladex (Goserelin Acetate)

2024 spending

$716K

Beneficiaries

105

466 claims

Per beneficiary

$6,823

$1,527.27 per unit

View as table
YearSpending
2020$852,389
2021$879,982
2022$849,015
2023$711,421
2024$716,394

Part B: Zoladex (Goserelin Acetate) · HCPCS J9202

2024 spending

$10.3M

Beneficiaries

2,048

8,842 claims

Per beneficiary

$5,032

2024 ASP limit $635.66 per unit

View as table
YearSpending
2020$10,161,257
2021$10,407,420
2022$10,966,920
2023$10,507,401
2024$10,305,181

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 518 on PubMed

Sponsor: Tersera

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.